Dapagliflozin

(Farxiga®)

Farxiga®

Drug updated on 12/11/2024

Dosage FormTablet (oral: 5 mg, 10 mg)
Drug ClassSodium-glucose co-transporter 2 (SGLT2) inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors
  • Indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
  • Indicated to reduce the risk of sustained eGFR decline, end stage kidney disease cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of 70 systematic review(s)/meta-analysis(es). [1-70]
  • Heart Failure with Preserved Ejection Fraction (HFpEF): Sodium-glucose co-transporter (SGLT)-2 inhibitors, including dapagliflozin, significantly reduced the risk of cardiovascular hospitalization in HFpEF patients without affecting cardiovascular mortality, with consistent efficacy across subgroups by estimated glomerular filtration rate (eGFR), systolic blood pressure, atrial fibrillation, diabetes status, sex, body mass index (BMI), and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels.
  • Type 2 Diabetes Mellitus (T2DM) with Cardiovascular and Renal Risks: Dapagliflozin and other SGLT-2 inhibitors effectively reduced hospitalizations for heart failure and showed benefits in improving cardiovascular outcomes among T2DM patients, with additional renal benefits like slower eGFR decline and reduced albuminuria in T2DM-associated chronic kidney disease (CKD).
  • CKD: Dapagliflozin was effective in CKD patients, slowing renal function decline and reducing albuminuria in both T2DM and non-diabetic CKD populations, with comparable efficacy to nintedanib in non-idiopathic pulmonary fibrosis (non-IPF) fibrosing interstitial lung diseases (ILDs).
  • Acute Kidney Injury (AKI): SGLT-2 inhibitors, including dapagliflozin, were associated with a reduced risk of AKI in patients with heart failure, without increasing the occurrence of hypotension or hypovolemia.
  • Genital and Urinary Tract Infections: Dapagliflozin and other SGLT-2 inhibitors showed an increased risk for genital infections and urinary tract infections, highlighting the need for monitoring in this area.
  • Diabetic Ketoacidosis (DKA): SGLT-2 inhibitors, particularly in type 1 diabetes, were linked with an increased incidence of DKA, indicating an elevated risk in this patient population.
  • Other Adverse Events: Dapagliflozin did not significantly raise the risk for volume depletion, renal impairment, fractures, or amputations, supporting a favorable safety profile in these areas.

Product Monograph / Prescribing Information

Document TitleYearSource
Farxiga (dapagliflozin) Prescribing Information.2024AstraZeneca Pharmaceuticals LP Wilmington, DE

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis2024Therapeutic Advances in Cardiovascular Disease
Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure in Patients With Type 2 Diabetes Mellitus: A Systematic Review2024 Cureus
Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis2024Sultan Qaboos University Medical Journal
Dapagliflozin in Heart Failure and Acute Myocardial Infarction: A Systematic Review of the Association in Diabetic Patients2024Cureus
Effect of SGLT-2 inhibitors on acute kidney injury in patients with heart failure: a systematic review and meta-analysis2024Diabetology & Metabolic Syndrome
Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Myocardial Infarction: A Meta-Analysis of Randomised Controlled Trials2024Endocrinology, Diabetes & Metabolism
Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review2024Journal of Diabetes Research
Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER2024Heart Failure
Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis2024Journal of Diabetes Research
Cardiovascular Outcomes With Empagliflozin and Dapagliflozin in Patients Without Diabetes2024The American Journal of Cardiology
Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis2024Frontiers in Endocrinology
Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER2024Journal of Cardiac Failure
Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials2023 African Health Sciences
Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials2023 Frontiers in Endocrinology
Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review2023Frontiers in Public Health
Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis2023Frontiers in Pharmacology
Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials2023Frontiers in Endocrinology
The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials2023BMC Endocrine Disorders
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials2023BMC Medicine
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials2023 Frontiers in Cardiovascular Medicine
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis2023Cardiovascular Diabetology
Effects of empagliflozin on serum uric acid level of patients with type 2 diabetes mellitus: a systematic review and meta-analysis2023Diabetology & Metabolic Syndrome
Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review2023Frontiers in Endocrinology
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials2023Frontiers in Endocrinology
Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis2023Global Heart
Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis2023European Heart Journal
Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoring2023Frontiers in Endocrinology
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials2023Medicina (Kaunas, Lithuania)
Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review2023The Journal of the International Society for Pharmacoeconomics and Outcomes Research
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER2023European Heart Journal
Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials2023Circulation
Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events2023 ESC Heart Failure
The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review2023 Cureus
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis2023Frontiers in Endocrinology
Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials2023Cardiovascular Diabetology
SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: A systematic review and meta-analysis2023Indian Heart Journal
A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors2023Pharmacometrics & Systems Pharmacology
Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials2023Heart Failure Reviews
Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials2022 Frontiers in Cardiovascular Medicine
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis2022World Journal of Cardiology
Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review2022Cost Effectiveness and Resource Allocation
Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials2022The Journal of Clinical Endocrinology and Metabolism
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER2022Nature Medicine
The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis2022 Frontiers in Pharmacology
The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review2022Cureus
The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis2022Journal of Thoracic Disease
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials2022Frontiers in Endocrinology
Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis2022Archives of Endocrinology and Metabolism
Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis2022Journal of Diabetes Research
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF2022JACC. Heart Failure
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials2022Advances in Therapy
Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis2022Journal of Cellular and Molecular Medicine
Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials2022Journal of Cardiovascular Pharmacology
Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis2022Clinical Research in Cardiology
Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review2021 Cureus
The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies2021African Health Sciences
Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials2021Oman Medical Journal
The Effects of Dapagliflozin in Patients With Heart Failure Complicated With Type 2 Diabetes: A Meta-Analysis of Placebo-Controlled Randomized Trials2021 Frontiers in Clinical Diabetes and Healthcare
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials2021 Frontiers in Public Health
Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis2021Cardiology Research and Practice
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis2021Endocrinology and Metabolism
Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials2021Frontiers in Endocrinology
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis2021 Medicine
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis2021Heart & Vasculature
[Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]2021Herz
Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials2021Heart Failure Reviews
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review2020Clinical and Experimental Hepatology
Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis2020Medicine
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies2020Diabetes Therapy
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis2020 PloS One

Clinical Practice Guidelines